Febit Exits Sequencing Market, Cuts 60 Percent of Workforce in Restructuring

A Febit official cited competition from larger companies, as well as the declining costs of whole-genome sequencing, which would eventually replace targeted resequencing, as reasons for discontinuing its sequence-capture and sequencing services businesses.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.

Related Stories